You are here: Industry Insights > RedHill

News List

RedHill Biopharma reports rise in Q3 2021 net revenues Pharmaceutical-Technology
December 02, 2021
RedHill Biopharma has reported net revenues of $21.6m in the third quarter (Q3) of this year, representing an increase from $21.5m in the second quarter of the year.
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients prnewswire
November 16, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the last patient has been enrolled in Part A of the Phase 2/3 study with novel...
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients prnewswire
September 23, 2021
While preliminary top-line data of the study efficacy endpoints showed consistent trends in favor of the opaganib arm, the study endpoints did not achieve statistical significance
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study prnasia
June 29, 2021
RedHill announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva®, ABC294640)[1].
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 prnasia
June 22, 2021
RedHill Biopharma Ltd. announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021.
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study prnasia
June 08, 2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe ...
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 prnasia
May 27, 2021
RedHill Biopharma Ltd. announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib[1] and RHB-107 (upamostat)[2] as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus.
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue prnewswire
April 12, 2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous ...
RedHill Announces Opaganib as Compassionate Use Treatment for COVID-19 americanpharmaceuticalreview
March 25, 2021
RedHill Biopharma has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.
ObvioHealth and RedHill to begin remote Covid-19 therapy trial pharmaceutical-technology
March 04, 2021
ObvioHealth is set to initiate a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for Covid-19 treatment.

Previous page 1 2 3 4 Next page